Search

Your search keyword '"Mizuaki Sakura"' showing total 2 results
Start Over Author "Mizuaki Sakura" Journal chemotherapy
2 results on '"Mizuaki Sakura"'

1. Contents Vol. 59, 2013

Author

Hideki Hayashi, Gloria Royo, Natividad López-Riquelme, Salomon M. Stemmer, Takashi Nishimura, Midori Ikeda, Ruth E Brown, Gali Perl, Pilar López, Antonio Galiana, Takashi Eto, Akitomi Shirato, Irit Ben-Aharon, Maria-Magdelana Balp, Noriyoshi Miura, Yuichi Sakamori, Iwao Fukui, Keisei Taku, Toshiyuki Iwata, Young Hak Kim, Arturo Soto-Matos, Hirotoshi Kikuchi, Chantelle Browne, Shinji Urakami, Kenichi Nishimura, Yuki Miyauchi, Mike Allen, Ryuichi Nakano, Mana Kamezato, Noemi Muszbek, Hiroki Nagai, Fotini Fligou, Pavel Novy, Takane Kikuchi-Ueda, Michiaki Mishima, Shinya Yamamoto, Hiroaki Ozasa, Hitoshi Masuda, Tetsuya Fukumoto, Takashi Daimon, Nozomu Tanji, Shigeru Tansho-Nagakawa, Ledicia Álvarez-Paredes, Junji Yonese, Markos Marangos, Hajime Tanaka, Ruth Chapman, Kriton S. Filos, Ian M. Gould, Tsuneyuki Ubagai, Yasuo Ono, Aron Popovtzer, Druckerei Stückle, Takeshi Yuasa, Evangelos D. Anastassiou, Carlos Fernandez Teruel, Iris Spiliopoulou, Tomoko Nishimura, Tadahiko Kikugawa, Yasuhisa Fujii, Yutaka Yanagihara, Efthimia Petinaki, Kazuyuki Inoue, Samnang Nguon, Koji Azuma, Kevin Marsh, Maung Maung Myat Moe, Satz Mengensatzproduktion, Ladislav Kokoska, Juan Carlos Rodríguez, Mizuaki Sakura, Liat Vidal, Masahiro Hatori, Montserrat Ruiz-García, Nikolaos Giormezis, Apostolos Liakopoulos, Masayoshi Yokoyama, Daiki Tsuji, Miguel Santibáñez, Kunihiko Itoh, Sofía Belda, Xiaoqin Mu, Matthaios Papadimitriou-Olivgeris, and Hironobu Sunadome

Subjects
Pharmacology, Infectious Diseases, Oncology, Drug Discovery, Pharmacology (medical), General Medicine
Published
2013
Full Text
View/download PDF

2. First-line combination chemotherapy with cisplatin, etoposide and ifosfamide for the treatment of disseminated germ cell cancer: re-evaluation in the granulocyte colony-stimulating factor era

Author

Shinya Yamamoto, Shinji Urakami, Yasuhisa Fujii, Hitoshi Masuda, Iwao Fukui, Mizuaki Sakura, Junji Yonese, Hajime Tanaka, and Takeshi Yuasa

Subjects
Adult, Male, Antineoplastic Agents, Mediastinal Neoplasms, Disease-Free Survival, Pharmacotherapy, Testicular Neoplasms, Drug Discovery, Granulocyte Colony-Stimulating Factor, Medicine, Humans, Pharmacology (medical), Ifosfamide, Retroperitoneal Neoplasms, Survival rate, Etoposide, Retrospective Studies, Pharmacology, Cisplatin, business.industry, Combination chemotherapy, General Medicine, Middle Aged, Neoplasms, Germ Cell and Embryonal, Hematologic Diseases, Granulocyte colony-stimulating factor, Survival Rate, Infectious Diseases, Oncology, Tolerability, Cancer research, Drug Therapy, Combination, business, hormones, hormone substitutes, and hormone antagonists, medicine.drug, Follow-Up Studies
Abstract

Background: This study re-evaluated the efficacy and tolerability of cisplatin, etoposide, and ifosfamide (VIP) combination chemotherapy as an alternative first-line regimen for patients with disseminated germ cell cancer (GCC) in this granulocyte colony-stimulating factor (G-CSF) era. Methods: The medical records of 91 consecutive patients with previously untreated disseminated GCC who received first-line VIP between 1995 and 2011 were retrospectively reviewed. Results: The 5-year overall survival rates for patients with good (n = 49), intermediate (n = 22) and poor (n = 20) prognoses according to the International Germ Cell Cancer Collaborative Group classification were 100, 79 and 83%, respectively. G-CSF was given to all patients, and no treatment-related deaths due to myelosuppression occurred. Conclusion: The present study is the first to examine the therapeutic outcomes and safety profile of first-line VIP after routine G-CSF use. VIP might be an alternative first-line regimen for patients with disseminated GCC in this G-CSF era.

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results